PNP
Purine nucleoside phosphorylase
As of the edition of 20 October 2026, PNP (purine nucleoside phosphorylase, UniProt P00491) has 3 drugs tested at it and 3 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00491
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 41
- Disease areas
- Immune system; Blood and lymph; Cancer; Inherited and neonatal; Bones, joints and muscles; Nutrition and metabolism; Infections; Urinary and reproductive
- Registered trials of its drugs
- 19
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Forodesine | Marketed | Phase 2 | none listed |
| Ulodesine | Went quiet | Phase 2 | none listed |
| Peldesine | Went quiet | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 3 |
| Total on the list | 3 |